BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/1/2014 10:54:00 AM | Browse: 1100 | Download: 1004
 |
Received |
|
2013-07-08 09:53 |
 |
Peer-Review Started |
|
2013-07-08 14:17 |
 |
To Make the First Decision |
|
2013-07-26 18:39 |
 |
Return for Revision |
|
2013-08-01 11:14 |
 |
Revised |
|
2013-08-14 10:23 |
 |
Second Decision |
|
2013-09-03 14:29 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2013-09-04 07:37 |
 |
Articles in Press |
|
|
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2013-09-29 14:12 |
 |
Publish the Manuscript Online |
|
2013-10-31 15:06 |
Category |
Dermatology |
Manuscript Type |
Minireviews |
Article Title |
Potential biomarkers for malignant melanoma
|
Manuscript Source |
Invited Manuscript |
All Author List |
Ye-Nan Wang, Yuki Yamamoto and Fukumi Furukawa |
Funding Agency and Grant Number |
|
Corresponding Author |
Ye-Nan Wang, MD, Department of Dermatology, Wakayama Medical University, 811-1, Kimiidera, Wakayama City, Wakayama 641-0012, Japan. wangyenan1112@live.cn |
Key Words |
Melanoma; Prognosis; Survival; Biological marker; Immunohistochemistry |
Core Tip |
Melanoma is one of the most common cancers and its high metastatic potential has a large impact on the number of melanoma deaths. Emerging molecular knowledge may lead to further identification of clinically relevant biomarkers, such as S100B, MIA, TA-90IC, 5-S-CD, SPARC, CSPG4, HSP105, IMP3, KIF2A, miR-221, YKL-40, some cancer stem cells (CD133, Nestin, CD166, CD20, CD271) and some monoclonal antibodies (KBA62, PNL2), for malignant melanoma detection, risk stratification and prediction/prognosis. However, all current markers have some shortcomings and thus we expect there will be more novel melanoma biomarkers discovered as supplementary diagnostic criteria in the near future. |
Publish Date |
2013-10-31 15:06 |
Citation |
Wang YN, Yamamoto Y, Furukawa F. Potential biomarkers for malignant melanoma. World J Dermatol 2013; 2(4): 44-50 |
URL |
http://www.wjgnet.com/2218-6190/full/v2/i4/44.htm |
DOI |
http://dx.doi.org/10.5314/wjd.v2.i4.44 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345